Drs. Amy Paller and Lisa Swanson discuss the risk of low bone mineral density and impaired growth reported in pediatric atopic dermatitis and observed improvements in growth with advanced therapy, especially among children of shorter stature at baseline.
Hear Dr. Lawrence Eichenfield share the recent consensus definitions from the International Eczema Council.
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.
Dr. Elena Netchiporouk illustrates key considerations for diagnosing CSU at EADV 2025.

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

In this video from the April 2025 WCPD symposium, Dr Amy Paller discusses the pathophysiology of skin barrier dysfunction in AD and how regulating IL-4 and IL-13 signaling may lead to restoration of the skin barrier. Dr Paller goes on to explore how reducing certain biomarkers, such as CCL17 (TARC), may reduce inflammation that contributes to AD severity in pediatric patients.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses emerging evidence that therapy-free disease control may be possible in atopic dermatitis, citing pediatric dupilumab data showing that a subset of patients-maintained remission after treatment discontinuation.
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025